Health Nova Leap Health Corp. Posts Record Q2 2026 Revenue, Income from Operating Activities and Adjusted EBITDA August 8, 2026
Health BlossomHill Therapeutics Announces Pricing of Upsized $150 Million Initial Public Offering August 7, 2026
Health Immune Mediated Disease Therapeutics Developer Attovia Therapeutics Debuts on Nasdaq August 6, 2026
Health LifeStance Reports Strong Second Quarter 2026 Financial Results and Raises Full Year Outlook August 6, 2026
Health UBRELVY® (ubrogepant) Recommended for Reimbursement by Canada’s Drug Agency (CDA-AMC) for Acute Migraine Treatment August 4, 2026